MIMEDX GROUP, INC.
MIMEDX develops and sells products used by clinicians to help treat chronic and other hard-to-heal wounds, burns, and surgical conditions. Its portfolio includes human placental tissue allografts such as EPIFIX, EPICORD and EPIEFFECT, processed using its PURION process, and products for surgical applications such as AMNIOEFFECT and AXIOFILL. MIMEDX also offers HELIOGEN, a bovine collagen matrix, and distributes wound-care products including RegenKit-Wound Gel, NovaForm Wound Matrix, G4Derm Plus and Hydrelix Collagen Matrix. MIMEDX sells through its direct sales team, independent sales agents and distributors. Customers include hospitals, wound care clinics, physician offices, ambulatory surgery centers and federal healthcare facilities. Distributors buy products at wholesale prices and resell them to providers and end users. MIMEDX is headquartered in Marietta, Georgia, where its manufacturing facilities process donated birth tissue.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MDXG in the last 30 days.
See all $MDXG insider activity →MiMedx Group reported Q3 Non-GAAP EPS of -$0.01 and revenue of $62.2M, down 45.3% year-over-year and $6.52M below estimates. The company defines free cash flow as operating cash flow minus capital expenditures.
MiMedx Group Inc. (MDXG) settled a patent dispute with a competitor, receiving $5M upfront and $5M annually for four years. The license is non-exclusive. MiMedx also reported a favorable patent reexamination decision. The company focuses on wound care, burn, and surgical products.
MiMedx Group (MDXG) reported a 71% drop in wound-care sales for Q3 2026, with surgical franchise sales growing mid-teens. Net sales were $XX million, gross profit $XX million, and net loss $XX million. The company expects 2026 net sales between $XX million and $XX million. MIMEDX also announced a favorable court ruling for AXIOFILL and a $25 million patent license agreement.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MDXG (MIMEDX GROUP, INC.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent MDXG coverage spans mergers & acquisitions, earnings and financial news.
Earnings miss likely triggers sell pressure.
The cash inflow improves near‑term liquidity and may lift the stock modestly.
Sales decline likely pressures the stock lower despite regulatory win.
Deal timing uncertainty rises, which can compress valuation multiples for both merger counterparties.
The regulatory request may delay or jeopardize the merger, likely pressuring MDXG shares lower in the short term.
AlphAI scores every news story that mentions MDXG with an AI model for sentiment and relevance, and aggregates insider trades from MIMEDX GROUP, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MiMedx Group reported Q3 Non-GAAP EPS of -$0.01 and revenue of $62.2M, down 45.3% year-over-year and $6.52M below estimates. The company defines free cash flow as operating cash flow minus capital expenditures.
1 min readMiMedx Group Inc. (MDXG) settled a patent dispute with a competitor, receiving $5M upfront and $5M annually for four years. The license is non-exclusive. MiMedx also reported a favorable patent reexamination decision. The company focuses on wound care, burn, and surgical products.
1 min readMiMedx Group (MDXG) reported a 71% drop in wound-care sales for Q3 2026, with surgical franchise sales growing mid-teens. Net sales were $XX million, gross profit $XX million, and net loss $XX million. The company expects 2026 net sales between $XX million and $XX million. MIMEDX also announced a favorable court ruling for AXIOFILL and a $25 million patent license agreement.
2 min readThe FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.
5 min readMIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously announced, MiMedx Group, Inc., a Florida corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanara MedTech Inc., a Texas corporation (“Sanara”), and Mustang Merger Sub, Inc., a wholly-owned
2 min readMiMedx Group (MDXG) will release its Q3 2026 financial results after market close on Oct. 28. A conference call and webcast will follow at 4:30 p.m. ET. The company specializes in wound care and surgical products.
1 min readMiMedx Group Inc. filed a Form S-4 with the SEC, effective September 4, 2026. The filing was accepted by the SEC on September 8, 2026. The company's CIK is 0001376339, and the file number is 333-298540.
1 min readSanara MedTech (SMTI) seeks shareholder approval for a merger with MiMedx. Shareholders will receive $33.00 in cash plus 0.4735 MiMedx shares per Sanara share, valued at roughly $35 per share. The merger requires shareholder approval at a September 30 meeting, with key shareholders already committing their votes in favor.
2 min readSanara MedTech (SMTI) agreed to be acquired by MiMedx Group. The deal, announced on July 29, 2026, is expected to close by year-end, subject to regulatory approvals and other conditions. Both companies will operate independently until the transaction is finalized.
2 min readSanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).
6 min read
